{"entity":{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","aka":["conditioning","conditioning chemotherapy","conditioning regimen","myeloablative","myeloablative conditioning","reduced-intensity","reduced-intensity conditioning","RIC","non-myeloablative","total body irradiation","TBI","busulfan-cyclophosphamide","BuCy","BuMel","BEAM","fludarabine-based conditioning","treosulfan-based"],"tldr":"The chemotherapy (with or without whole-body radiation) given in the days before a stem cell transplant to destroy the diseased marrow and, for donor transplants, suppress the patient's immune system so the graft is not rejected.","summary":"Myeloablative conditioning (busulfan-cyclophosphamide, cyclophosphamide-TBI, high-dose melphalan for myeloma, BEAM for lymphoma) gives maximal anti-leukaemic effect but is tolerable only under about 60; reduced-intensity and non-myeloablative regimens (fludarabine-based, low-dose TBI, treosulfan) rely on the donor immune effect and have extended allogeneic transplant to older patients at the cost of higher relapse. Regimen choice is a trade-off between relapse and toxicity (mucositis, organ damage, infertility, veno-occlusive disease). Lymphodepletion before CAR-T is a milder cousin of the same idea.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation#Conditioning_regimens"}],"tags":[],"related":["allogeneic-transplant","autologous-transplant","lymphodepletion","gray-unit","mucositis"],"cancers":[],"sections":["cell-therapy","chemotherapy"],"technologies":[],"targets":[],"drugs":["melphalan","cyclophosphamide","treosulfan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Treatment jargon"},"route":"/terms/conditioning-regimen/","neighbours":{"term":[{"id":"alkylating-agent","kind":"term","name":"Alkylating agents and antimetabolites","route":"/terms/alkylating-agent/"},{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/"},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/"},{"id":"gvhd","kind":"term","name":"Graft-versus-host disease (GVHD) and graft-versus-leukaemia","route":"/terms/gvhd/"},{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/"},{"id":"lymphodepletion","kind":"term","name":"Lymphodepletion before CAR-T","route":"/terms/lymphodepletion/"},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/"}],"technology":[{"id":"rejuv-tx-bone-eyes-kidneys-lungs","kind":"technology","name":"Bone, eyes, kidneys and lungs after transplant","route":"/technologies/rejuv-tx-bone-eyes-kidneys-lungs/"},{"id":"gvhd-chronic-overview","kind":"technology","name":"Chronic graft-versus-host disease","route":"/technologies/gvhd-chronic-overview/"},{"id":"rejuv-tx-fertility-and-growth","kind":"technology","name":"Fertility, growth and what total body irradiation costs","route":"/technologies/rejuv-tx-fertility-and-growth/"},{"id":"rejuv-tx-endocrine-and-cardiometabolic","kind":"technology","name":"Hormones, metabolism and the heart after transplant","route":"/technologies/rejuv-tx-endocrine-and-cardiometabolic/"},{"id":"rejuv-tx-late-effects-overview","kind":"technology","name":"Late effects after a stem cell transplant","route":"/technologies/rejuv-tx-late-effects-overview/"},{"id":"gvhd-prophylaxis","kind":"technology","name":"Preventing graft-versus-host disease, and what prevention costs","route":"/technologies/gvhd-prophylaxis/"},{"id":"rejuv-tx-second-cancers","kind":"technology","name":"Second cancers after allogeneic transplant","route":"/technologies/rejuv-tx-second-cancers/"}],"cancer":[{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}]}}